初诊恶性实体肿瘤患者贫血的影响因素

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (675 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the factors related to anemia in patients with newly diagnosed malignant solid tumors.Methods The clinical data on 401 newly diagnosed patients with malignant solid tumors admitted to our department between May 2014 and May 2019 was reviewed. The effect of gender, age, types of tumors, tumor stage,KPS scores, albumin, cholesterol, C-reactive protein (CRP) and ferritin on the occurrence of anemia was analyzed.Results Among the 401 patients, 224 were males (55.9%), 177 were females (44.1%), the median age was 71 years (28-95 years), and 251 (62.6%) were diagnosed with anemia. Univariate analysis showed that age over 60, urinary system tumors, tumor stage Ⅳ, a KPS score <70 points, albumin <40 g/L, normal cholesterol levels, and elevated CRP and ferritin levels could increase the chance of anemia (P<0.05). Multivariate logistic regression analysis showed that hypoalbuminemia(OR=6.981,95%CI 3.914-12.450) and KPS score <70(OR=1.835,95%CI 1.028-3.274) were independent risk factors for anemia in patients with newly diagnosed malignant solid tumors. KPS scores and serum levels of albumin and cholesterol were positively correlated with hemoglobin concentrations, while age, CRP and ferritin levels were negatively correlated.Conclusions The incidence of anemia in newly diagnosed patients with malignant solid tumors is high, which has different causes. Hypoalbuminemia and a KPS score <70 are independent risk factors for anemia in patients with newly diagnosed malignant solid tumors.

Key words： newly diagnosed malignant solid tumor anemia influencing factors

Received: 15 January 2021

ZTFLH:

R730.6

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Fang
	XU Wenyan
	LIU Li
	REN Xiuhong
	LIU Pingping
	ZHENG Li
	ZHANG Hao
	ZHANG Songsong
	XU Yaru
	GUO Zhenxing

Cite this article:

WANG Fang,XU Wenyan,LIU Li等. Influencing factors of anemia in newly diagnosed patients with malignant solid tumors[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(8): 702-706.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2021/V32/I8/702

[1]	Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature[J]. Am J Med, 2004,116 (Suppl 7A):11S-26S.
[2]	宋正波, 陆舜, 冯继锋, 等. 中国肿瘤相关性贫血发生率及治疗现状的流行病学调查研究[J]. 中国肿瘤, 2019,28(9):718-722.
[3]	张之南, 沈悌. 血液病诊断及疗效标准[M]. 北京:科学出版社, 2007: 1-4.
[4]	Gascon P, Rodriguez C A, Valentin V, et al. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study[J]. Support Care Cancer, 2013,21(11):3039-3049.
[5]	Littlewood T J. Management options for cancer therapy-related anaemia[J]. Drug Saf, 2002,25(7):525-535.
[6]	Watine J, Bouarioua N. Anemia as an independent prognostic factor for survival in patients with cancer[J]. Cancer, 2002,94(10):2793-2797.
[7]	Qiu M Z, Xu R H, Ruan D Y, et al. Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China[J]. Tumour Biol, 2010,31(6):633-641.
[8]	Paitan V, Alcarraz C, Leonardo A, et al. Anemia as a prognostic factor in cancer patients[J]. Rev Peru Med Exp Salud Publica, 2018, 35(2): 250-258.
[9]	Ludwig H, Van Belle S, Barrett-Lee P, et al. The european cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients[J]. Eur J Cancer, 2004, 40(15): 2293-2306.
[10]	Maccio A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study[J]. Haematologica, 2015, 100(1): 124-132.
[11]	于雷. 恶性肿瘤患者发生贫血的危险因素分析[J]. 中国肿瘤, 2013,22(5):403-405.
[12]	马军, 王杰军, 张力, 等. 肿瘤相关性贫血临床实践指南(2015-2016版)[J]. 中国实用内科杂志, 2016,36(S1):1-21.
[13]	黄晓东, 易俊林, 高黎, 等. 放疗前贫血对鼻咽癌预后的影响[J]. 中华放射肿瘤学杂志, 2006,15(2):73-76.
[14]	Hung S C, Tung T Y, Yang C S, et al. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients[J]. Am J Kidney Dis, 2005, 45(6):1073-1083.
[15]	Adamson J W. The anemia of inflammation/malignancy: mechanisms and management[J]. ASH Education Program Book, 2008, 2008(1): 159-165.
[16]	Weiss G, Goodnough L T. Anemia of chronic disease[J]. N Engl J Med, 2005,352(10):1011-1023.
[17]	Madu A J, Ughasoro M D. Anaemia of chronic disease: an in-depth review[J]. Med Princ Pract, 2017, 26(1):1-9.
[18]	Falkensammer C E, Thurnher M, Leonhartsberger N, et al. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival[J]. BJU Int, 2011, 107(12):1893-1898.
[19]	Rossi E. Hepcidin--the iron regulatory hormone[J]. Clin Biochem Rev, 2005, 26(3): 47-49.
[20]	Singh B, Arora S, Agrawal P, et al. Hepcidin: a novel peptide hormone regulating iron metabolism[J]. Clin Chim Acta, 2011, 412(11-12): 823-830.
[21]	Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation[J]. Blood, 2003, 102(3):783-788.
[22]	Andriopoulos B J, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism[J]. Nat Genet, 2009, 41(4):482-487.
[23]	Park C H, Valore E V, Waring A J, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver[J]. J Biol Chem, 2001, 276(11):7806-7810.
[24]	Wrighting D M, Andrews N C. Interleukin-6 induces hepcidin expression through STAT3[J]. Blood, 2006, 108(9): 3204-3209.
[25]	Maccio A, Madeddu C, Massa D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia[J]. Blood, 2005, 106(1):362-367.
[26]	Blay J Y, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma[J]. Cancer Res, 1992, 52(12): 3317-3322.